Status:
TERMINATED
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborating Sponsors:
Sanofi
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
This is a phase I/II study. The phase I portion of the study will determine the maximum tolerated dose of bortezomib when administered in combination with carboplatin \& docetaxel and to determine the...
Detailed Description
A chemotherapy efficacy plateau' has been reached for the treatment of patients with advanced or metastatic non-small cell lung cancer. Platinum-based two-drug combination is considered the current st...
Eligibility Criteria
Inclusion
- Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC
- Age \> 18 years
- ECOG PS \< 2
- No prior chemotherapy
- Measurable disease
- Signed informed consent
- Adequate bone marrow function
- Adequate renal function
- Adequate hepatic function
Exclusion
- Untreated clinically active brain metastasis
- Radiotherapy within 2 weeks prior to initiation of protocol therapy
- Treatment with any investigational therapy within 4 weeks prior to enrollment
- History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma on situ of the cervix) within the last 5 years
- Patients in their reproductive age group should use an effective method of birth control. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. Patients who are breast-feeding will be excluded from the study. Women of childbearing potential must have a negative pregnancy test.
- Major surgery within 3 weeks prior to enrollment
- Use of immunosuppressive agents including systemic corticosteroids within 4 weeks prior to enrollment (corticosteroids are permitted as physiological replacement therapy or as supportive care for nausea and emesis)
- Known history of Human immunodeficiency virus infection
- Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
- Concurrent serious medical infection or illness, or psychiatric illness likely to interfere with participation in this clinical study.
- History of known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80, bortezomib, boron or mannitol
- Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.
- Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00714246
Start Date
October 1 2008
End Date
May 1 2013
Last Update
June 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033